Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/52045
Campo DC Valoridioma
dc.contributor.authorPérez, Antonioen_US
dc.contributor.authorWägner, Ana Mariaen_US
dc.contributor.authorCarreras, Gemmaen_US
dc.contributor.authorGiménez, Gabrielen_US
dc.contributor.authorSánchez-Quesada, Jose Luisen_US
dc.contributor.authorRigla, Mercedesen_US
dc.contributor.authorGómez-Gerique, Juan Antonioen_US
dc.contributor.authorPou, Jose Mariaen_US
dc.contributor.authorDe Leiva, Albertoen_US
dc.date.accessioned2018-11-25T16:59:02Z-
dc.date.available2018-11-25T16:59:02Z-
dc.date.issued2000en_US
dc.identifier.issn0003-9926en_US
dc.identifier.urihttp://hdl.handle.net/10553/52045-
dc.description.abstractBackground Data on the prevalence of dyslipidemia in type 1 diabetes mellitus are scarce and are based on total triglyceride and total cholesterol concentrations alone. Objective To assess the effect of glycemic optimization on the prevalence of dyslipidemia and low-density lipoprotein cholesterol (LDL-C) concentrations requiring intervention in patients with type 1 diabetes. Patients A total of 334 adults with type 1 diabetes and 803 nondiabetic control subjects. Methods Levels of glycosylated hemoglobin, total cholesterol, total triglyceride, high-density lipoprotein cholesterol (HDL-C), and LDL-C were assessed at baseline and after 3 to 6 months of intensive therapy with multiple insulin doses. Results Levels of LDL-C greater than 4.13 mmol/L (>160 mg/dL) and total triglyceride greater than 2.25 mmol/L (>200 mg/dL) and low HDL-C levels (<0.9 mmol/L [<35 mg/dL] in men or <1.1 mmol/L [<45 mg/dL] in women) were found in 16%, 5%, and 20% of patients and 13%, 6%, and 9% of controls, respectively (P<.001 for HDL-C). Diabetic women showed more hypercholesterolemia than nondiabetic women (15.6% vs 8.5%; P = .04). After glycemic optimization (mean ± SD glycosylated hemoglobin decrease, 2.2 ± 1.96 percentage points), the prevalence of LDL-C levels greater than 4.13 mmol/L (>160 mg/dL) became lower in diabetic men than in nondiabetic men (9.7% vs 17.5%; P = .04), but women showed frequencies of dyslipidemia similar to their nondiabetic counterparts. The proportion of patients with LDL-C concentrations requiring lifestyle (>2.6 mmol/L [>100 mg/dL]) or drug (>3.4 mmol/L [>130 mg/dL]) intervention decreased from 78% and 42% to 66% and 26%, respectively. Conclusions Low HDL-C is the most frequent dyslipidemic disorder in patients with poorly controlled insulin-treated type 1 diabetes, and a high proportion show LDL-C levels requiring intervention. Less favorable lipid profiles could explain the absence of sex protection in diabetic women. The improvement caused by glycemic optimization puts forward intensive therapy as the initial treatment of choice for dyslipidemia in poorly controlled type 1 diabetes.en_US
dc.languageengen_US
dc.relation.ispartofArchives of internal medicine (1960)en_US
dc.sourceArchives of Internal Medicine[ISSN 0003-9926],v. 160(18), p. 2756-2762 (Octubre 2000)en_US
dc.subject32 Ciencias médicasen_US
dc.subject3205 Medicina internaen_US
dc.subject320502 Endocrinologíaen_US
dc.subject.otherDyslipidemiaen_US
dc.subject.otherDiabetes mellitusen_US
dc.subject.otherGlycosylated hemoglobinen_US
dc.subject.otherCholesterolen_US
dc.subject.otherLipoproteinen_US
dc.titlePrevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus: Effect of glycemic controlen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1001/archinte.160.18.2756en_US
dc.identifier.scopus0034626386-
dc.contributor.authorscopusid7402509742-
dc.contributor.authorscopusid7401456520-
dc.contributor.authorscopusid6603602740-
dc.contributor.authorscopusid23970533700-
dc.contributor.authorscopusid6603877734-
dc.contributor.authorscopusid6603627533-
dc.contributor.authorscopusid7003411647-
dc.contributor.authorscopusid14322294200-
dc.contributor.authorscopusid7005846734-
dc.description.lastpage2762en_US
dc.identifier.issue18-
dc.description.firstpage2756en_US
dc.relation.volume160en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.description.numberofpages7en_US
dc.utils.revisionen_US
dc.date.coverdateOctubre 2000en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.jcr6,055-
dc.description.jcrqQ1-
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptGIR IUIBS: Diabetes y endocrinología aplicada-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-7663-9308-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameWägner, Anna Maria Claudia-
Colección:Artículos
Vista resumida

Citas SCOPUSTM   

62
actualizado el 17-nov-2024

Citas de WEB OF SCIENCETM
Citations

57
actualizado el 17-nov-2024

Visitas

34
actualizado el 10-feb-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.